SG11201702596YA - Compositions and methods of use for augmented immune response and cancer therapy - Google Patents

Compositions and methods of use for augmented immune response and cancer therapy

Info

Publication number
SG11201702596YA
SG11201702596YA SG11201702596YA SG11201702596YA SG11201702596YA SG 11201702596Y A SG11201702596Y A SG 11201702596YA SG 11201702596Y A SG11201702596Y A SG 11201702596YA SG 11201702596Y A SG11201702596Y A SG 11201702596YA SG 11201702596Y A SG11201702596Y A SG 11201702596YA
Authority
SG
Singapore
Prior art keywords
compositions
methods
use
immune response
cancer therapy
Prior art date
Application number
SG11201702596YA
Inventor
Jennifer Brogdon
Daniela Cipolletta
Glenn Dranoff
Deborah A Knee
Fei Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462061644P priority Critical
Priority to US201562198673P priority
Priority to US201562220764P priority
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to PCT/US2015/054775 priority patent/WO2016057846A1/en
Publication of SG11201702596YA publication Critical patent/SG11201702596YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11201702596YA 2014-10-08 2015-10-08 Compositions and methods of use for augmented immune response and cancer therapy SG11201702596YA (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201462061644P true 2014-10-08 2014-10-08
US201562198673P true 2015-07-29 2015-07-29
US201562220764P true 2015-09-18 2015-09-18
PCT/US2015/054775 WO2016057846A1 (en) 2014-10-08 2015-10-08 Compositions and methods of use for augmented immune response and cancer therapy

Publications (1)

Publication Number Publication Date
SG11201702596YA true SG11201702596YA (en) 2017-04-27

Family

ID=54347879

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702596YA SG11201702596YA (en) 2014-10-08 2015-10-08 Compositions and methods of use for augmented immune response and cancer therapy

Country Status (19)

Country Link
US (2) US20170306037A1 (en)
EP (2) EP3204419A1 (en)
JP (1) JP2017535257A (en)
KR (1) KR20170065029A (en)
CN (1) CN107001476A (en)
AU (2) AU2015330771B2 (en)
BR (1) BR112017007093A2 (en)
CA (1) CA2964146A1 (en)
CL (2) CL2017000836A1 (en)
CR (1) CR20170138A (en)
CU (1) CU24437B1 (en)
EA (1) EA201790799A1 (en)
IL (1) IL251435D0 (en)
MX (1) MX2017004669A (en)
PE (1) PE16542017A1 (en)
PH (1) PH12017500634A1 (en)
SG (1) SG11201702596YA (en)
TN (1) TN2017000120A1 (en)
WO (2) WO2016057841A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3081576B1 (en) 2013-12-12 2019-08-21 Shanghai Hengrui Pharmaceutical Co., Ltd. Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2016012779A (en) 2014-03-31 2017-04-27 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists.
EA201692458A1 (en) 2014-05-28 2017-06-30 Агенус Инк. Anti-gitr antibodies and methods of their application
EP3253890A4 (en) 2015-02-03 2018-06-27 Oncomed Pharmaceuticals, Inc. Tnfrsf-binding agents and uses thereof
WO2017015623A2 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
KR20180088907A (en) 2015-12-17 2018-08-07 노파르티스 아게 Antibody molecules to PD-1 and uses thereof
CA3030765A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
GB201619652D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel polypeptides
CA3051797A1 (en) * 2017-01-27 2018-08-02 Ultrahuman One Limited Binding agents
CN109689691A (en) * 2017-02-10 2019-04-26 优特力克斯有限公司 IFN-γ-inductivity regulatory T-cell can convertibility anticancer (IRTCA) antibody and its application
AU2018226646A1 (en) * 2017-03-03 2019-09-19 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag Antibody Conjugates comprising receptor agonists toll-like and combination therapies
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag Bis cyclic compound dinucleotide 2'-5'-r-- (3'fa) (3'fa) and uses thereof
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
US20190031766A1 (en) 2017-06-22 2019-01-31 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019018640A1 (en) * 2017-07-21 2019-01-24 Novartis Ag Dosage regimens for anti-gitr antibodies and uses thereof
EP3476390A1 (en) * 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
TW201922291A (en) 2017-11-16 2019-06-16 瑞士商諾華公司 Combination therapies
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019183040A1 (en) 2018-03-21 2019-09-26 Five Prime Therapeutics, Inc. ANTIBODIES BINDING TO VISTA AT ACIDIC pH
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
WO2019200229A1 (en) 2018-04-13 2019-10-17 Novartis Ag Dosage regimens for anti-pd-l1 antibodies and uses thereof

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Denaturation antibody, or improvements relating modified antibody
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500329A (en) 1987-05-21 1990-02-08
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ES2059558T3 (en) 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins and their use as pharmaceuticals.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified interleukin-2, and a method of producing
AT135370T (en) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemically modified granulocyte colony-causing factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derived albumin has therapeutic function
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ES2096749T3 (en) 1990-12-14 1997-03-16 Cell Genesys Inc Chimerical chains for signal transduction pathways associated with a receiver.
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical compositions containing them.
FR2686901A1 (en) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa New antithrombotic polypeptides, their preparation and pharmaceutical compositions containing them.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0640094A1 (en) 1992-04-24 1995-03-01 Board Of Regents The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP1975181B1 (en) 1992-10-28 2011-02-16 Genentech, Inc. Use of vascular endothelial cell growth factor antagonists
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CN1117155C (en) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 Novel compounds
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AT279947T (en) 1996-03-18 2004-11-15 Univ Texas Immunoglobulin-like domain with increased half-lives
MY129541A (en) 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
AT397660T (en) 1996-08-16 2008-06-15 Schering Corp Cell surface antigen from mammals and related reagents
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DK0973804T3 (en) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF antibodies
AT476664T (en) 1997-04-07 2010-08-15 Genentech Inc Anti-vegf antibodies
ES2258817T3 (en) 1997-05-21 2006-09-01 Biovation Limited Method for the production of non-immunogen proteins.
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag Crystal modification a N-phenyl-2- pyrimidinamine, processes for their manufacture and use
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
CA2308114A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
AU2591599A (en) 1998-02-09 1999-08-23 Genentech Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (en) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CA2359067C (en) 1999-01-15 2017-03-14 Genentech, Inc. Polypeptide variants with altered effector function
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
DE19932688B4 (en) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design of beta-sheet proteins of gamma-II-crystalline antibody-like
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
PL211461B1 (en) 2001-10-30 2012-05-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP4727992B2 (en) 2002-11-15 2011-07-20 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
KR101166749B1 (en) 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 Isoxazole compounds as inhibitors of heat shock proteins
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
MXPA05012475A (en) 2003-05-23 2006-05-25 Wyeth Corp Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof.
DE10324447A1 (en) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generation of artificial binding proteins on the basis of ubiquitin
RU2005136988A (en) 2003-05-30 2006-06-10 Дженентек, Инк. (Us) Treatment of anti-vegf
WO2005007190A1 (en) 2003-07-11 2005-01-27 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
WO2005039549A1 (en) 2003-10-27 2005-05-06 Novartis Ag Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
EP1692318A4 (en) 2003-12-02 2008-04-02 Genzyme Corp Compositions and methods to diagnose and treat lung cancer
ES2689328T3 (en) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
JP4782700B2 (en) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド Transfer of antibody specificity using minimally required binding determinants
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
RS55546B1 (en) 2004-05-13 2017-05-31 Icos Corp Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2343380B1 (en) 2004-11-16 2019-06-12 Humanigen, Inc. Immunoglobulin variable region cassette exchange
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
EP1866339B1 (en) 2005-03-25 2013-05-29 GITR, Inc. Gitr binding molecules and uses therefor
PT2650020T (en) 2005-05-06 2016-12-12 Providence Health & Services - Oregon Trimeric ox40-immunoglobulin fusion protein and methods of use
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
GT200600381A (en) 2005-08-25 2007-03-28 organic compounds
PE04272007A1 (en) 2005-08-30 2007-04-21 Novartis Ag Compounds substituted benzimidazoles derivatives as tyrosine kinase inhibitors
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
CL2006003348A1 (en) 2005-12-02 2008-02-22 Mount Sinai Medical Ct Of New York University Chimeric avian influenza virus; method of producing an immunogenic composition; and method for inducing an immune response to two infectious agents in a bird or human.
SG179430A1 (en) 2005-12-13 2012-04-27 Incyte Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JP5539649B2 (en) 2005-12-13 2014-07-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Scaffold for cell transplantation
EP1963368B1 (en) 2005-12-13 2012-07-18 Eli Lilly And Company Anti-il-17 antibodies
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
SI2010528T1 (en) 2006-04-19 2018-02-28 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
JO2883B1 (en) 2006-05-05 2015-03-15 اي ار ام ال ال سي Compounds And Compositions As Hedgehog Pathway Modulators
PE02242011A1 (en) 2006-08-02 2011-04-05 Novartis Ag PROCEDURE FOR SYNTHESIS OF A Smac peptidomimetic IAP inhibitor, and compounds intermediates for the synthesis of Himself
NZ574138A (en) 2006-08-18 2012-01-12 Xoma Technology Ltd Prlr-specific antibody and uses thereof
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
RS57741B1 (en) 2006-11-22 2018-12-31 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
WO2008070743A2 (en) 2006-12-05 2008-06-12 Memgen Llc Methods of increasing cancer sensitivity to chemotherapeutic agents using chimeric isf35
CN103641816A (en) 2006-12-08 2014-03-19 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
US20100178684A1 (en) 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
MX2009014199A (en) 2007-06-18 2010-05-24 Organon Nv Antibodies to human programmed death receptor pd-1.
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
NZ599338A (en) 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
EP3124046A1 (en) 2007-07-12 2017-02-01 GITR, Inc. Combination therapies employing gitr binding molecules
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
AU2009215188B2 (en) 2008-02-13 2014-09-18 Dana-Farber Cancer Institute, Inc. Continuous cell programming devices
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
AR070924A1 (en) 2008-03-19 2010-05-12 Novartis Ag and two crystalline forms of solvated forms of lactic acid salts of 4- amino -5- fluoro-3- (5- (4-methylpiperazin-1-yl) -1H- benzimidazol-2-yl) quinolin-2- (1H) - one
EA021364B1 (en) 2008-05-21 2015-06-30 Инсайт Корпорейшн SALT 2-FLUORO-N-METHYL-4- [7- (quinolin-6-ylmethyl) imidazo [1,2-b] [1,2,4] triazin-2-yl] benzamide AND METHODS FOR THEIR PREPARATION
JP5351254B2 (en) 2008-05-23 2013-11-27 ノバルティス アーゲー Quinoxaline- and quinoline-carboxamide derivatives
UY31929A (en) 2008-06-25 2010-01-05 Irm Llc Compounds and compositions as kinase inhibitors
WO2010003118A1 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
NZ590258A (en) 2008-07-08 2013-10-25 Intellikine Llc Kinase inhibitors and methods of use
BRPI0915928A2 (en) 2008-07-17 2015-11-03 Novartis Ag COMPOSITIONS and METHODS OF USE FOR THERAPEUTIC ANTIBODIES
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc human antibodies that bind to the gene 3 of lymphocyte activation (LAG-3) and uses these
PE04192011A1 (en) 2008-08-22 2011-07-13 Novartis Ag Pyrrolo-pyrimidine as cdk inhibitors
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
CN102203132A (en) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Compositions of PD-1 antagonists and methods of use
MX2011002365A (en) 2008-09-02 2011-04-04 Novartis Ag Picolinamide derivatives as kinase inhibitors.
EA018863B1 (en) 2008-09-10 2013-11-29 Новартис Аг organic compounds
WO2010030002A1 (en) 2008-09-12 2010-03-18 国立大学法人三重大学 Cell capable of expressing exogenous gitr ligand
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
CA2744937C (en) 2008-11-28 2017-02-28 Novartis Ag Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
KR20190069615A (en) 2008-12-09 2019-06-19 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2393921B1 (en) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
JP5844159B2 (en) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille PD-1 antibody and PD-L1 antibody and use thereof
JO2933B1 (en) 2009-03-02 2015-09-15 اي ار ام ال ال سي Compositions and methods for ‎modulating the wnt signaling ‎pathway
AR078228A1 (en) 2009-06-26 2011-10-26 Novartis Ag CYP17 inhibitors
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
EP3023438A1 (en) 2009-09-03 2016-05-25 Merck Sharp & Dohme Corp. Anti-gitr antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JP5851419B2 (en) 2009-12-29 2016-02-03 エマージェント プロダクト デベロップメント シアトル, エルエルシー Heterodimer binding proteins and uses thereof
UY33227A (en) 2010-02-19 2011-09-30 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of CDK4 / 6
TR201807750T4 (en) 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antibody.
WO2012004367A1 (en) 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
ES2630328T3 (en) 2010-08-23 2017-08-21 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and procedures for their use
EP2918607B1 (en) 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
CN103237565B (en) 2010-10-06 2017-10-31 哈佛学院董事会 Pore-forming hydrogel for the injectable of the cell therapy based on material
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
EP2714073A4 (en) 2011-06-03 2014-12-31 Harvard College In situ antigen-generating cancer vaccine
WO2013039954A1 (en) * 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
SG11201402603WA (en) 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
CA2861107A1 (en) 2012-01-13 2013-07-18 President And Fellows Of Harvard College Controlled delivery of tlr agonists in structural polymeric devices
UY34591A (en) 2012-01-26 2013-09-02 Novartis Ag Compounds imidazopirrolidinona
UY34632A (en) 2012-02-24 2013-05-31 Novartis Ag Oxazolidin-2-one compounds and uses thereof
CN106074368B (en) 2012-03-29 2019-01-22 先进癌症治疗有限责任公司 PFKFB3 inhibitor and method as anticancer therapeutic agent
US9937249B2 (en) 2012-04-16 2018-04-10 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
WO2013158292A1 (en) 2012-04-17 2013-10-24 University Of Washington Through Its Center For Commercialization Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
CN104302638B (en) 2012-05-15 2016-08-24 诺华股份有限公司 For inhibiting abl1, benzamide derivatives and abl2 activity of bcr-abl1
BR112014027244A2 (en) 2012-05-15 2017-06-27 Novartis Ag benzamide derivatives for inhibition of abl1, abl2 and bcr-abl1 activity
CA2871332A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
KR20150014452A (en) 2012-05-15 2015-02-06 노파르티스 아게 Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
JO3300B1 (en) 2012-06-06 2018-09-16 Novartis Ag Compounds and compositions for modulating egfr activity
KR101549637B1 (en) 2012-06-08 2015-09-03 국립암센터 Novel epitope for switching to Th1 cell and use thereof
AR091649A1 (en) 2012-07-02 2015-02-18 Squibb Bristol Myers Co Optimization of antibodies that bind to the gene activation lymphocyte 3 (LAG-3) and their uses
CN103566377A (en) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 Targeted immunotherapy for cancer
TWI472974B (en) 2012-09-06 2015-02-11 Au Optronics Corp Method for detecting touch points of multi-type objects
JP6359019B2 (en) 2012-10-24 2018-07-18 ノバルティス アーゲー IL-15Rα type, cells expressing IL-15Rα type, and therapeutic use of IL-15Rα and IL-15 / IL-15Rα complex
CN104994850A (en) 2012-11-08 2015-10-21 诺华股份有限公司 Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
AU2013352406A1 (en) 2012-11-28 2015-06-04 Novartis Ag Combination therapy
UA117575C2 (en) 2013-02-08 2018-08-27 Новартіс Аг An antibody that specifically binds to il-17a and its application
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
KR20150131224A (en) 2013-03-14 2015-11-24 노파르티스 아게 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
BR112015021414A2 (en) 2013-03-14 2017-07-18 Icahn School Med Mount Sinai newcastle disease virus and its uses
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
BR112015028341A2 (en) 2013-05-18 2017-07-25 Aduro Biotech Inc compositions and methods for activating "interferon gene stimulator-dependent signaling"
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulation of tumor immunity
MX355480B (en) 2013-11-01 2018-04-19 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors.
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
CU24427B1 (en) 2014-01-31 2019-06-04 Children´S Medical Center Corp Antibody molecules bind tim-3
CA2936962A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof

Also Published As

Publication number Publication date
CR20170138A (en) 2017-08-21
AU2019200346A1 (en) 2019-02-07
CU24437B1 (en) 2019-09-04
PE16542017A1 (en) 2017-11-13
JP2017535257A (en) 2017-11-30
CU20170045A7 (en) 2017-09-06
KR20170065029A (en) 2017-06-12
MX2017004669A (en) 2017-06-19
CA2964146A1 (en) 2016-04-14
EA201790799A1 (en) 2017-08-31
US20170306038A1 (en) 2017-10-26
WO2016057841A1 (en) 2016-04-14
BR112017007093A2 (en) 2018-03-06
PH12017500634A1 (en) 2017-09-25
TN2017000120A1 (en) 2018-07-04
CL2017000836A1 (en) 2017-09-15
CL2018001369A1 (en) 2018-07-27
AU2015330771A1 (en) 2017-04-20
US20170306037A1 (en) 2017-10-26
EP3204419A1 (en) 2017-08-16
WO2016057846A1 (en) 2016-04-14
EP3204421A1 (en) 2017-08-16
AU2015330771B2 (en) 2018-10-18
CN107001476A (en) 2017-08-01
IL251435D0 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
SG11201703950PA (en) Anti-pd-1 antibodies and methods of use thereof
IL247845D0 (en) Antibody compositions for tumor treatment
SG11201608077PA (en) Treatment of nafld and nash
SG11201703561QA (en) Anti-tim3 antibodies and methods of use
IL247898D0 (en) Anti-ox40 antibodies and methods of use
GB2525793B (en) Keratin treatment formulations and methods
SG11201707192XA (en) Therapeutic antibodies and their uses
EP3094352A4 (en) Compositions and methods for treatment and detection of cancers
EP3245225A4 (en) Compositions and methods for treatment and detection of cancers
IL251821D0 (en) Cannabis extracts and methods of preparing and using same
ZA201800941B (en) Anti-tigit antibodies and methods of use
IL251435D0 (en) Compositions and methods of use for augmented immune response and cancer therapy
LT3161128T (en) Methods and compositions for targeted genetic modifications and methods of use
SG11201605432RA (en) Determinants of cancer response to immunotherapy
EP3137105A4 (en) Combination vaccine devices and methods of killing cancer cells
EP3169363A4 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
IL260257D0 (en) Compositions and methods for the treatment of hemoglobinopathies
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
HK1216991A1 (en) Cancer vaccines and methods of treatment using the same
SG11201606625RA (en) Immunotherapy of cancer through combination of local and systemic immune stimulation
GB201519858D0 (en) Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
PT3105253T (en) Anti-jagged1 antibodies and methods of use
IL252688D0 (en) Facilitating sending and receiving of peer-to-business payments
ZA201708589B (en) Factor xi antibodies and methods of use
SG11201706583PA (en) Anti-pvrig antibodies and methods of use